Blood test may predict Crohn's drug success
NCT ID NCT03142321
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at whether certain proteins in the blood can predict if the drug vedolizumab (Entyvio) will reduce inflammation in the small bowel of people with Crohn's disease. Researchers used MRI scans to measure changes in the bowel wall after treatment. The goal is to help doctors choose the right treatment earlier for each patient.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vedolizumab (Entyvio) injection
- What this could lead to
- If successful, this could help doctors predict which patients with small bowel Crohn's will respond to vedolizumab, allowing more personalized treatment.
- What could go wrong
- This is a small, completed Phase 4 study focused on finding biomarkers, not proving a new treatment works. The results may not apply to all Crohn's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
48 people
The number who actually took part.
- Started
-
Jun 2018
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Moderate to severe disease activity small bowel CD (small bowel only or ileocecal only) visible on MRE * Initiated on Vedolizumab with/without thiopurines or methotrexate * ≥18 years old Exclusion Criteria: * Pregnancy * Age \<18 * Planned surgery prior to the first follow-up MRE * Inability to provide informed consent. * Perianal CD will be excluded since assessment requires performance of additional MRI of the pelvis. * Individuals with colonic involvement other than involvement of the ascending colon and cecum. * Inpatient scans will only be included if this is a MRE and adequate small bowel distension with appropriate contrast has been achieved * If unable to provide informed consent * Contraindications for MRE including chronic kidney disease that precludes contrast administration, implanted medical devices that are contraindicated for MRE.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease of small intestine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.